Clinical study of low-molecular-weight heparin combined with ligustrazine in treatment of early- onset severe preeclampsia

Clinical study of low-molecular-weight heparin combined with ligustrazine in treatment of early-onset severe preeclampsia

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004583

Enrollment

Unknown

Registered

2014-04-29

Start date

2014-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early-onset severe preeclampsia

Interventions

Group A:LMWH+ligustrazine

Group B:LMWH

Group C:ligustrazine

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. gestational age (less than 34 weeks); 2. severe preeclampsia; 3. without internal, surgical complications; 4. initial illness; 5. singleton pregnancies.

Exclusion criteria

Exclusion criteria: 1. Complicated with a history of allergies or allergic heparin; 2. Complicated with hemorrhage disease; 3. the abnormal liver function; 4. the expected operation or delivery within 24 h.

Design outcomes

Primary

Measure	Time frame
pressure;Urinary protein;Routine blood test;Liver function;Renal function;Blood rheology;Coagulation series;	—

Secondary

Measure	Time frame
B-mode ultrasonography;The fundus ocule;	—

Countries

China

Contacts

Public ContactXu Yong-ping

Second Hospital of Shandong University

xuyongping1117@sina.com+86 15153169289

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026